{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:44:00Z","timestamp":1794375840862,"version":"4.9.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/100007489","name":"Bausch & Lomb Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2018,3,4]]},"DOI":"10.1080\/14656566.2018.1439920","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T05:16:43Z","timestamp":1518239803000},"page":"337-353","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":38,"title":["Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid"],"prefix":"10.1080","volume":"19","author":[{"given":"Timothy L.","family":"Comstock","sequence":"first","affiliation":[{"name":"Ophthalmic Medical Affairs Consultant, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Virginia Eye Consultants, Norfolk, VA, USA"},{"name":"Eastern Virginia Medical School, Norfolk, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225010-00004"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.0067"},{"key":"e_1_3_4_5_1","volume-title":"Ocular therapeutics and drug delivery","author":"Bartlett MA","year":"1996","unstructured":"Bartlett MA, Reddy IK. Clinical pharmacology of the anterior segment of the eye. In: Reddy IK, editor. Ocular therapeutics and drug delivery. Lancaster, Pennsylvania: Technomic Publishing Company; 1996."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00297-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-013-0020-5"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/789623"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00223a017"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.5772\/48380"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015849132396"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02272.x"},{"issue":"2","key":"e_1_3_4_14_1","first-page":"115","article-title":"Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory corticosteroid","volume":"2","author":"Alberth M","year":"1991","unstructured":"Alberth M, Wu WM, Winwood D, et al. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory corticosteroid. J Biopharma Sci. 1991;2(2):115\u2013125.","journal-title":"J Biopharma Sci"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713689109020329"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111599"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070479"},{"issue":"13","key":"e_1_3_4_18_1","first-page":"1980","article-title":"Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax\u00ae) in rabbits with corneal inflammation","volume":"51","author":"Glogowski S","year":"2010","unstructured":"Glogowski S, Proksch J. Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax\u00ae) in rabbits with corneal inflammation. Invest Ophthalmol Vis Sci. 2010;51(13):1980.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0142"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1998.14.153"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713689209001808"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2004.20.533"},{"key":"e_1_3_4_23_1","first-page":"6297","article-title":"Anti-inflammatory effects of the glucocorticoid loteprednol etabonate in human ocular and inflammatory cells","volume":"55","author":"Vollmer TR","year":"2014","unstructured":"Vollmer TR, Cavet M, Harrington KL, et al. Anti-inflammatory effects of the glucocorticoid loteprednol etabonate in human ocular and inflammatory cells. Invest Ophthalmol Vis Sci. 2014;55(13):6297.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000311"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713689308999455"},{"issue":"1","key":"e_1_3_4_26_1","first-page":"31","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis","volume":"23","author":"Asbell P","year":"1997","unstructured":"Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Clao J. 1997;23(1):31\u201336.","journal-title":"Clao J"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70171-0"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70094-6"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71128-6"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90077-5"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80007-8"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.024"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21882"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-012-0152-5"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00034-3"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.052"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.08.015"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000436"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000049"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0085"},{"key":"e_1_3_4_41_1","unstructured":"RESTASIS\u00ae (cyclosporine ophthalmic emulsion) 0.05% prescribing information. Allergan Inc.; Irvine California. June 2013"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S30261"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(98)80170-3"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)99054-6"},{"key":"e_1_3_4_45_1","unstructured":"Comstock TL Usner DW Effect of loteprednol etabonate ophthalmic suspension 0.5% on post-operative pain and discomfort. In Proceedings of the American Society of Cataract and Refractive Surgery Meeting 2010."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(01)01185-3"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2012.10.039"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.200161"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253898"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.659723"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1115879"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02849993"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.2165\/11596320-000000000-00000"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2016.0264"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S30278"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078001034.x"},{"issue":"5","key":"e_1_3_4_57_1","first-page":"177","article-title":"Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery","volume":"5","author":"Comstock TL","year":"2011","unstructured":"Comstock TL, Paterno MR, Singh A, et al. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5(5):177\u2013186.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S55259"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S40588"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2012.09.013"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S32643"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0059-7"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S94332"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S138272"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000407"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000475"},{"key":"e_1_3_4_67_1","volume-title":"Loteprednol etabonate ophthalmic gel 0.5% for inflammation associated with dry eye disease: outcomes of a 12-week phase 2 clinical study","author":"Evans DG","year":"2017","unstructured":"Evans DG, Sheppard JD, Williams JI. Loteprednol etabonate ophthalmic gel 0.5% for inflammation associated with dry eye disease: outcomes of a 12-week phase 2 clinical study. Washington DC: Annual Meeting of the American Optometric Association; 2017."},{"key":"e_1_3_4_68_1","unstructured":"Opitz DL Evola C Paradesi A et al. Efficacy of loteprednol etabonate ophthalmic gel 0.5% for the treatment of evaporative dry eye and meibomian gland dysfunction. Presented at the American Academy of Optometry October 7-10 2015 New Orleans LA"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0315-8"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1993.9.157"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181a3c52f"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ICL.0000092071.82938.46"},{"key":"e_1_3_4_73_1","unstructured":"Cavet ME Sanfilippo CM DeCory HH. Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate. Invest Ophthalmol Vis Sci. 2017;58(8):1082."},{"issue":"7","key":"e_1_3_4_74_1","first-page":"1524","article-title":"Ocular pharmacokinetics of submicron loteprednol etabonate ophthalmic gel, 0.38% following topical administration in rabbits","volume":"56","author":"Cavet ME","year":"2015","unstructured":"Cavet ME, Glogowski S, DiSalvo C, et al. Ocular pharmacokinetics of submicron loteprednol etabonate ophthalmic gel, 0.38% following topical administration in rabbits. Invest Ophthalmol Vis Sci. 2015;56(7):1524.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-014-0021-z"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S62659"},{"key":"e_1_3_4_77_1","unstructured":"Sheppard JD Brady T Foster CS et al. A randomized comparator-controlled phase 2 clinical trial of ADX-102 ophthalmic solution in noninfectious anterior uveitis. Invest Ophthalmol Vis Sci. 2017;58(8):1231."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2018.1439920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:30:30Z","timestamp":1770942630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2018.1439920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3,4]]}},"alternative-id":["10.1080\/14656566.2018.1439920"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2018.1439920","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}